Table 2.
RNAi in clinical trials (based on Ref. 153).
|
Company |
Disease |
Product |
Status |
|---|---|---|---|
|
Sirna/MERCK |
AMD |
Sirna‐027/AGN211745 |
phase II |
|
Quark Pharma. (Pfizer) |
AMD |
RTP801i‐14 |
phase I/II |
|
Opko Health |
AMD |
Bevasiranib |
phase III |
|
Benitec/City of Hope |
HIV/AIDS |
Lentivirus vector |
phase I |
|
Nucleonics Inc. |
HBV |
NUC B1000 |
phase I |
|
Alnylam Pharma. |
RSV |
ALN‐RSV‐02 |
phase II |
|
Senetek PLC |
glioblastoma multiforme |
ATN‐RNA |
phase I |
|
Calando Pharma. |
solid tumors |
CALAA‐01 |
phase I |
|
Quark Pharma. |
acute renal failure |
AKli‐5 |
phase I |
|
TransDerm Inc. |
pachyonychia congenita |
TD101 |
phase Ib |
|
Santaris Pharma. |
HCV |
SPC3649 |
phase I |